The products will be distributed over a 2 year period and will allow Ascendis to further secure its leading position in the supply of antibiotics to the State. The tender covers specialist first generation molecules which are first line treatments used by the state to combat infections, which still present the biggest disease burden for the country.
Ascendis will commence distribution towards the end of November 2015 in tandem with a national education program regarding antibiotic stewardship. The program is aimed at healthcare practitioners at government hospitals and clinics and will reinforce the judicial use of antibiotics to combat resistance.
The tender award will also allow economies of scale for the same products into the dispensing doctors market and allow Ascendis Health to further focus on accessibility and affordability of its generic products.
Dr Karsten Wellner, CEO of Ascendis Health comments; “ We are extremely pleased to have secured this important tender, as it is a clear indication of the success of our integration strategies by unlocking value across the production and supply chain, allowing us to offer a growing range of world class products at competitive pricing.”
The announcement follows hot on the heels of the acquisition by Ascendis of Spanish pharmaceutical group Famalider who specializes in the development and manufacture of generic pharmaceuticals, as well as the acquisition of 85 already MCC registered generics, that are currently not marketed, from Sandoz South Africa.